[HTML][HTML] Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia
R Shahswar, G Beutel, R Gabdoulline… - …, 2024 - ncbi.nlm.nih.gov
Abstract Treatment options for relapsed and refractory acute myeloid leukemia patients (R/R
AML) are limited. This retrospective cohort study compares safety and efficacy of …
AML) are limited. This retrospective cohort study compares safety and efficacy of …
In silico molecular dynamics docking of drugs to the inhibitory active site of SARS-CoV-2 protease and their predicted toxicology and ADME
L Peterson - Available at SSRN 3580951, 2020 - papers.ssrn.com
A in silico molecular dynamics (MD) docking investigation was conducted to identify drugs
(ligands) which could potentially be of interest for repurposing. We sought ligands which …
(ligands) which could potentially be of interest for repurposing. We sought ligands which …
Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia
S Zhong, H Kurish, R Walchack, H Li, J Edwards… - Leukemia Research, 2024 - Elsevier
Background/rationale Most patients with acute myeloid leukemia (AML) develop relapsed or
refractory (R/R) disease after receiving initial induction chemotherapy. Salvage …
refractory (R/R) disease after receiving initial induction chemotherapy. Salvage …
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients
Relapsed or refractory (R/R) acute myeloid leukemia (AML) has a poor prognosis, and new
therapies are a major clinical need. When mutated, FLT3 drives neoplastic cell proliferation …
therapies are a major clinical need. When mutated, FLT3 drives neoplastic cell proliferation …
The Applications of Mitoxantrone and Its Liposome in Adult Acute Myeloid Leukemia
G Song, J Gu, Y Chen, Y Zhang… - Open Journal of …, 2023 - publish7promo.com
Acute myeloid leukemia (AML), a rapidly progressing hematopoietic malignancy, can only
be cured hopefully by hematopoietic stem cells transplantation (HSCT). Before HSCT, we …
be cured hopefully by hematopoietic stem cells transplantation (HSCT). Before HSCT, we …
[PDF][PDF] African Journal of Pharmaceutical Sciences
LE Peterson - 2022 - researchgate.net
Abstract An in silico Molecular Dynamics (MD) docking investigation with 4,634 drugs was
conducted to identify potential repurposing for therapeutic treatment of Covid-19 disease …
conducted to identify potential repurposing for therapeutic treatment of Covid-19 disease …